ATRC

NEUTRALAnalyst

AtriCure, Inc.

2026-09-18

Price

$58.10

-1.73%

This is the 2026-09-18 snapshot — the signals and analysis for ATRC as of this single trading day.

View full ATRC research hub →

Score3.8Watchlist

Signals4/8 DNA0/13 Act · 3/4 Risk

SentimentNEUTRALScore: 8

Volume6.3xvs 20d avg

Analysis

AtriCure (ATRC) is undergoing high-conviction price discovery triggered by Stifel's September 17th price target hike to $65 and growing physician favorability for its LAAM technology. The stock's massive 6.2x volume surge and 'PERFECT_STACK' technical setup confirm that institutions are aggressively absorbing overhead supply, completely ignoring noise around insider selling and valuation concerns. Supported by a RISK_ON macro regime with ultra-tight credit spreads, this high-beta medical device play is perfectly positioned to leverage abundant market liquidity.

Fired Signals

SURGEGOLDEN CROSSMARKET LEADERPERFECT STACKWEAK FINISHEXTENSIONDISTRIBUTION

Key Takeaways

Actionable Thesis: Accumulate ATRC on the back of institutional momentum and recent structural analyst upgrades tied to LAAM technology adoption [1.2.7].
Key Risk: Elevated valuation multiples and recent insider selling could introduce headline friction if market liquidity dries up.
What to Watch: Price action around the recent 52-week high of $59.59; a decisive breakout confirms the next leg up, while $48.17 acts as the hard stop.

← Back to 2026-09-18 View Full ATRC History →Yahoo Finance &nearr;